Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.81 -1.2%	$4.70	$1.14 ▼ $7.20	$348.02M	0.76	944,607 shs	1.03 million shs
AMRN Amarin	$15.98 +1.0%	$15.44	$7.08 ▼ $17.49	$330.95M	0.84	69,537 shs	44,615 shs
BNTC Benitec Biopharma	$12.99 +2.3%	$12.58	$8.06 ▼ $17.15	$340.99M	0.4	43,150 shs	74,167 shs
LIMN Liminatus Pharma	$3.41 +22.7%	$6.75	$2.53 ▼ $33.66	$88.69M	N/A	2.21 million shs	35.51 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+7.79%	+12.38%	+161.71%	+4.31%
AMRN Amarin	0.00%	+2.11%	+3.83%	+43.83%	+27.11%
BNTC Benitec Biopharma	0.00%	-0.15%	+16.19%	-1.52%	+43.54%
LIMN Liminatus Pharma	0.00%	-14.75%	-60.85%	+340,999,900.00%	+340,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.0997 of 5 stars	3.3	1.0	0.0	0.0	2.7	1.7	0.6
AMRN Amarin	0.2907 of 5 stars	0.5	2.0	0.0	0.0	2.8	0.0	0.6
BNTC Benitec Biopharma	1.3908 of 5 stars	3.6	1.0	0.0	0.0	1.5	0.8	0.0
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	63.51% Upside
AMRN Amarin	1.00	Sell	$12.00	-24.91% Downside
BNTC Benitec Biopharma	3.13	Buy	$26.00	100.15% Upside
LIMN Liminatus Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIMN, BNTC, ALDX, and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
AMRN Amarin	$228.61M	1.45	N/A	N/A	$23.62 per share	0.68
BNTC Benitec Biopharma	$80K	4,262.34	N/A	N/A	$4.68 per share	2.78
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
AMRN Amarin	-$82.18M	-$3.67	N/A	N/A	N/A	-47.22%	-21.18%	-15.00%	10/29/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
LIMN Liminatus Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest LIMN, BNTC, ALDX, and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A
7/30/2025	Q2 2025	AMRN Amarin	-$0.66	-$0.03	+$0.63	-$0.03	$45.45 million	$72.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
AMRN Amarin	N/A	3.26	2.34
BNTC Benitec Biopharma	0.01	14.80	14.80
LIMN Liminatus Pharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
AMRN Amarin	22.25%
BNTC Benitec Biopharma	52.19%
LIMN Liminatus Pharma	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
AMRN Amarin	1.96%
BNTC Benitec Biopharma	1.30%
LIMN Liminatus Pharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
AMRN Amarin	360	20.71 million	20.30 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
LIMN Liminatus Pharma	N/A	26.01 million	N/A	N/A

LIMN, BNTC, ALDX, and AMRN Headlines

Recent News About These Companies

Liminatus Pharma (NASDAQ:LIMN) Downgraded to "Sell" Rating by Wall Street Zen

August 2, 2025 | marketbeat.com

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

July 28, 2025 | financialpost.comF

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

July 28, 2025 | globenewswire.com

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

July 25, 2025 | globenewswire.com

Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

July 24, 2025 | globenewswire.com

Liminatus Pharma: CD47 Hasn't Worked For Anyone, But Is This The Exception?

June 24, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, BNTC, ALDX, and AMRN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.81 -0.07 (-1.19%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.84 +0.03 (+0.53%)

As of 07:00 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Amarin NASDAQ:AMRN

$15.98 +0.16 (+1.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.98 0.00 (0.00%)

As of 08/22/2025 04:45 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Benitec Biopharma NASDAQ:BNTC

$12.99 +0.29 (+2.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.98 -0.01 (-0.08%)

As of 08/22/2025 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Liminatus Pharma NASDAQ:LIMN

$3.41 +0.63 (+22.66%)

As of 08/22/2025 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time